Interviews

Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.

The director of the National Eye Institute discusses recent advances, AI, and evolving standards of care in ophthalmology.

Duration of benefit "has to be part of the discussion," emphasizes Rogers of The James/The Ohio State Comprehensive Cancer Center.

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.

Cathy Eng, MD, discusses a BREAKWATER post hoc analysis showing poorer survival in early-onset BRAF V600E colorectal cancer.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses AP-led clinics, managing talquetamab taste changes, and infection prophylaxis with bispecifics.

Joanna Parga-Belinkie, MD, of CHOP explains how she tailors counseling to address vitamin K shot misinformation and VKDB risks.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Transplant is no longer the default for young, fit patients with a good donor if they achieve MRD-negative status, says Emily K. Curran, MD

Zidesamtinib offers a new treatment option for previously treated ROS1-positive NSCLC, with rapid, durable responses and strong brain activity.

In the inaugural episode, AON's Fred Divers, MD, explains why the network exited CMS's Enhancing Oncology Model over opaque benchmarks, data delays and shifting rules.

Geoffrey Chupp, MD, explains how IL-5 and IL-4Rα biologics are reshaping COPD care and why eosinophil requirements still limit access.

Michael Wechsler, MD, MMSc, explains how anti-IL-5 therapies studied in the MIRRA and MANDARA trials are reducing steroid use in EGPA.

Cathy Eng, MD, explains how young adults with cancer face career, fertility, and body image concerns as well as where to find support.

In part 2, Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, discusses how earlier referrals, AI, and less prior authorization can improve cancer outcomes.

Gray market peptides often contain far less drug than labeled and may carry toxins like arsenic, warns Catherine Varney, DO.

MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

AI, patient voice in pathways, and caregiver support are shaping community oncology, AON leaders said at Patient-Centered Oncology Care.

Jeffery A. Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine questions.

Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, says Catherine Varney, DO.

Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma.

Geoffrey Chupp, MD, of Yale Medicine explains how a blood RNA study shows T2-low asthma is more complex than clinicians generally think.

Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC, discusses how data builds payer trust, reduces prior authorization, and expands access in community oncology.

Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock vaccines.

Sean Wharton, MD, PharmD, discusses new data on survodutide from the phase 3 SYNCHRONIZE-2 trial.

Policy mandates and low-burden trial designs are key to equitable stem cell transplant access, explains Karilyn Larkin, MD.

Cathy Eng, MD, FACP, FASCO, says young patients with colorectal cancer often look healthy and present at stage IV, making symptom awareness critical.

As US measles cases top 3600, Christina Madison, PharmD, explains how pharmacists can counter vaccine misinformation and rebuild trust.